Bryan R Haugen1, Erik K Alexander2, Keith C Bible3, Gerard M Doherty4, Susan J Mandel5, Yuri E Nikiforov6, Furio Pacini7, Gregory W Randolph8, Anna M Sawka9, Martin Schlumberger10, Kathryn G Schuff11, Steven I Sherman12, Julie Ann Sosa13, David L Steward14, R Michael Tuttle15, Leonard Wartofsky16. 1. 1 University of Colorado School of Medicine , Aurora, Colorado. 2. 2 Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts. 3. 3 The Mayo Clinic , Rochester, Minnesota. 4. 4 Boston Medical Center , Boston, Massachusetts. 5. 5 Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania. 6. 6 University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania. 7. 7 The University of Siena , Siena, Italy . 8. 8 Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital , Harvard Medical School, Boston, Massachusetts. 9. 9 University Health Network, University of Toronto , Toronto, Ontario, Canada . 10. 10 Institute Gustave Roussy and University Paris Sud , Villejuif, France . 11. 11 Oregon Health and Science University , Portland, Oregon. 12. 12 University of Texas M.D. Anderson Cancer Center , Houston, Texas. 13. 13 Duke University School of Medicine , Durham, North Carolina. 14. 14 University of Cincinnati Medical Center , Cincinnati, Ohio. 15. 15 Memorial Sloan Kettering Cancer Center , New York, New York. 16. 16 MedStar Washington Hospital Center , Washington, DC.
Abstract
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. METHODS: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members. RESULTS: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research. CONCLUSIONS: We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.
BACKGROUND: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the American Thyroid Association's (ATA's) guidelines for the management of these disorders were revised in 2009, significant scientific advances have occurred in the field. The aim of these guidelines is to inform clinicians, patients, researchers, and health policy makers on published evidence relating to the diagnosis and management of thyroid nodules and differentiated thyroid cancer. METHODS: The specific clinical questions addressed in these guidelines were based on prior versions of the guidelines, stakeholder input, and input of task force members. Task force panel members were educated on knowledge synthesis methods, including electronic database searching, review and selection of relevant citations, and critical appraisal of selected studies. Published English language articles on adults were eligible for inclusion. The American College of Physicians Guideline Grading System was used for critical appraisal of evidence and grading strength of recommendations for therapeutic interventions. We developed a similarly formatted system to appraise the quality of such studies and resultant recommendations. The guideline panel had complete editorial independence from the ATA. Competing interests of guideline task force members were regularly updated, managed, and communicated to the ATA and task force members. RESULTS: The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, use of molecular markers, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to screening for thyroid cancer, staging and risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using imaging and serum thyroglobulin, thyroid hormone therapy, management of recurrent and metastatic disease, consideration for clinical trials and targeted therapy, as well as directions for future research. CONCLUSIONS: We have developed evidence-based recommendations to inform clinical decision-making in the management of thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.
Authors: Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park Journal: Cancer Date: 2011-08-31 Impact factor: 6.860
Authors: Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland Journal: J Natl Compr Canc Netw Date: 2011-11 Impact factor: 11.908
Authors: Jeffrey Liu; Bhuvanesh Singh; Giovanni Tallini; Diane L Carlson; Nora Katabi; Ashok Shaha; R Michael Tuttle; Ronald A Ghossein Journal: Cancer Date: 2006-09-15 Impact factor: 6.860
Authors: R Elisei; M Schlumberger; A Driedger; C Reiners; R T Kloos; S I Sherman; B Haugen; C Corone; E Molinaro; L Grasso; S Leboulleux; I Rachinsky; M Luster; M Lassmann; N L Busaidy; R L Wahl; F Pacini; S Y Cho; J Magner; A Pinchera; P W Ladenson Journal: J Clin Endocrinol Metab Date: 2009-10-22 Impact factor: 5.958
Authors: Mary Ann O'Brien; Timothy J Whelan; Miguel Villasis-Keever; Amiram Gafni; Cathy Charles; Robin Roberts; Susan Schiff; Wenjie Cai Journal: J Clin Oncol Date: 2009-01-05 Impact factor: 44.544
Authors: Kathryn G Schuff; Stephen M Weber; Babak Givi; Mary H Samuels; Peter E Andersen; James I Cohen Journal: Laryngoscope Date: 2008-05 Impact factor: 3.325
Authors: Juan P Brito; Michael R Gionfriddo; Alaa Al Nofal; Kasey R Boehmer; Aaron L Leppin; Carl Reading; Matthew Callstrom; Tarig A Elraiyah; Larry J Prokop; Marius N Stan; M Hassan Murad; John C Morris; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2013-11-25 Impact factor: 5.958
Authors: Soo Young Kim; Bup-Woo Kim; Ju Yeon Pyo; Soon Won Hong; Hang-Seok Chang; Cheong Soo Park Journal: World J Surg Date: 2018-01 Impact factor: 3.352
Authors: Tania Jaber; Steven G Waguespack; Maria E Cabanillas; Mohamed Elbanan; Thinh Vu; Ramona Dadu; Steven I Sherman; Moran Amit; Elmer B Santos; Mark Zafereo; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958
Authors: R Gelmini; M Campanelli; F Cabry; A Franceschetto; G Ceresini; L Ruffini; A Zaccaroni; P Del Rio Journal: J Endocrinol Invest Date: 2017-08-31 Impact factor: 4.256
Authors: Nicholas S Andresen; John M Buatti; Hamed H Tewfik; Nitin A Pagedar; Carryn M Anderson; John M Watkins Journal: Eur Thyroid J Date: 2017-03-23
Authors: Min Ji Jeon; Sung Min Chun; Ji-Young Lee; Kyeong Woon Choi; Deokhoon Kim; Tae Yong Kim; Se Jin Jang; Won Bae Kim; Young Kee Shong; Dong Eun Song; Won Gu Kim Journal: Endocrine Date: 2019-01-15 Impact factor: 3.633
Authors: Bin Xu; Talia Fuchs; Snjezana Dogan; Iñigo Landa; Nora Katabi; James A Fagin; R Michael Tuttle; Eric Sherman; Anthony J Gill; Ronald Ghossein Journal: Thyroid Date: 2020-05-08 Impact factor: 6.568